Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy

Abstract Background 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a decrease in left ventricular ejection fraction. The aim of this study is...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc, Gregory Aune
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-05-01
Colecção:	Cardio-Oncology
Assuntos:	Predictive Model Cardiotoxicity Trastuzumab Breast Cancer
Acesso em linha:	https://doi.org/10.1186/s40959-023-00177-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!